Michael Dell (Richard Drew/AP Images)

$200M SPAC fund­ed by bil­lion­aire Michael Dell will un­wind af­ter fail­ing to find a part­ner

The bio­phar­ma in­dus­try may be do­ing deals again, but SPACs are be­ing left out of the re­cent wave.

Ori­on Biotech Op­por­tu­ni­ties Corp., a blank check ve­hi­cle fund­ed in part by tech bil­lion­aire Michael Dell’s fam­i­ly firm, an­nounced Mon­day it will dis­solve on May 17 and re­turn in­vest­ments to share­hold­ers af­ter be­ing un­able to find a merg­er part­ner. As of April 20, the SPAC’s trust ac­count held rough­ly $205 mil­lion, ac­cord­ing to a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.